

August 11, 2010

U.S. Nuclear Regulatory Commission Region III
Radioactive Materials Licensing Section
2443 Warrenville Road, Suite 210
Lisle, IL 60532-4352

RE: NRC License 24-11858-01

To Whom It May Concern,

This is to notify you, in compliance with 10 CFR 35.14, of changes in our authorized users.

The following authorized user has discontinued performance of duties under the license:

Anna L. Fu, M.D.

We would like to add Vincent Q. Joe, MD as an authorized user to our license. He is currently an authorized user for 10 CFR 35.400 under NRC license No. 24-13383-01. A copy of that license is enclosed.


We would also like to amend our license to include the following two sealed source materials permitted by 10 CFR 35.400 under item 7.D along with the other sources listed on the current license.

1. Bard Brachytherapy Inc. Source, Model STM 1251
 - a. Sealed Source Registry Number is IL-1074-S-101-S
2. IsoAid LLC, Model IAPd-103A (advantage)

RECEIVED AUG 24 2010

If you have any questions regarding this matter, please do not hesitate to call me at 636-496-4600.

Sincerely,



Andre Strzembosz, MD
Radiation Safety Officer



Sherry Hausmann, President
St. Clare Health Center

Enclosure

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 55

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Christian Hospital 2. 11133 Dunn Road St. Louis, MO 63136		In accordance with letter dated April 8, 2010, 3. License number 24-13383-01 is amended in its entirety to read as follows: 4. Expiration date April 30, 2011 5. Docket No. 030-02382 Reference No.	
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed	
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed	
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. As needed (not to exceed 1 curie of iodine-131)	
D. Any byproduct material permitted by 10 CFR 35.400	D. See Item 9.D.	D. 4 curies total	
E. Any byproduct material permitted by 10 CFR 31.11	E. Prepackaged kits	E. As needed	
F. Depleted Uranium	F. Cadmium plated metal	F. 999 kilograms total possession limit	
G. Iodine-125 as permitted by 10 CFR 35.1000	G. Liquid as Iotrex TM	G. As needed	

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.

Official Use Only – Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 of 4 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number

24-13383-01

Docket or Reference Number

030-02382

Amendment No. 55

- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400 using the following sealed sources; 3M Model 6D6C, Medi-Physics Model 6DCT1, Best Medical International, Model 81-01, North American Scientific Model Med 3633 (Mentor), Theragenics Corp. Model 200, Mills Biopharmaceuticals, Inc. Model 103SL (Prostaseed), International Brachytherapy SA Model 1031L, Best International, Inc. Models 2331-2335, Syncor Pharmaceuticals, BT-125-1, Medi-Physics, Inc. Models 6733 (Echosed) and 6711 (Oncosed), International Brachytherapy SA Model 1251L, IsoAid, L.L.C. Model IAI-125 (Advantage), Implant Sciences Corp. 3500 (I-plant), North American Scientific Model Med 3631 (Mentor) Mills Biopharmaceuticals, Inc. Model I-125 SL (Prostaseed) and Best Medical International, Inc. Models 2301 to 2316)
- E. In vitro studies.
- F. Shielding in a linear accelerator.
- G. For use in the Proxima Therapeutics' GliaSite® Radiotherapy System for medical use permitted by 10 CFR 35.1000.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at
- A. Licensed material shall be received, stored, and used at 11133 Dunn Road, St. Louis, Missouri.
 - B. Licensed material in Subitem 6.F. may be used at 11155 Dunn Road, Suite 101E, St. Louis, Missouri.
 - C. Licensed material in Subitem 6.D. may be received and stored at 11155 Dunn Road, Suite 101E, St. Louis, Missouri.
11. The Radiation Safety Officer for this license is John J. Chorzel, M.S.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14
 - B. The following individuals are authorized users for medical use as indicated:

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 of 4 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number

24-13383-01

Docket or Reference Number

030-02382

Amendment No. 55

Authorized Users

Paul Busse, M.D.

Chandrakant C. Taylor, M.D.

Wenzel Vas, M.D.

Harry G. Greditzer III, M.D.

James V. Piepho, M.D.

John L. Rollo, M.D.

Gregory King, M.D.

Vincent Q. Joe, M.D.

Anjum Shariff, M.D.

Paul W. Hargan, M.D.

Veena D. Divecha, M.D.

Material and Use

10 CFR 35.100 and 35.200

10 CFR 35.100 and 35.200

10 CFR 35.100, 35.200 and 31.11.

10 CFR 35.100, 35.200, 35.300 and 35.500.

10 CFR 35.300 and 35.400

10 CFR 31.11.

10 CFR 31.11.

10 CFR 35.400 and iodine-125 in the Proxima
Therapeutics' GliaSite® Radiotherapy system.

10 CFR 35.100 and 35.200

10 CFR 35.100, 35.200 and 35.300.

10 CFR 35.400

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
- 14.
15. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance
16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

MATERIALS LICENSING
SUPPLEMENTARY STATEMENT

License Number

24-13383-01

Docket or Reference Number

030-02382

Amendment No. 55

A. Application dated October 13, 2000 and,


B. Letters dated October 9, 2000 (and attachments), November 8, 2000, March 22, 2001, April 3, 2001, April 18, 2001, May 11, 2001, November 1, 2001, June 30, 2005, October 3, 2005, November 29, 2006, January 12, 2007 and March 2, 2007.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date

MAY 07 2010

By


James R. Mullauer, M.H.S.
Materials Licensing Branch
Region III


 **SSM Cancer Care**

1011 Bowles Avenue
Suite G50 Dept 4910
Fenton, Missouri 63026

ES, FOLD HERE
CERTIFIED MAIL™



7009 2820 0002 9513 6262



neopost

049J82052446

\$ 05.71₀

02/20/2010

Mailed From 63144

US POSTAGE

US Nuclear Regulatory Commission, Region III
Radioactive Materials Licensing
2443 Warrenville Road, Suite 210
Lisle, IL 60532-4352